Foundation for Prader-Willi Research
14
3
3
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
14.3%
2 terminated/withdrawn out of 14 trials
80.0%
-6.5% vs industry average
7%
1 trials in Phase 3/4
50%
4 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
Role: collaborator
Impact of Bright Light Therapy on Prader-Willi Syndrome
Role: collaborator
Cerebellar TMS and Satiety in Prader-Willi Syndrome
Role: collaborator
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
Role: lead
Mitochondrial Complex I Dysfunction in PWS
Role: collaborator
Natural History Study of Serious Medical Events in PWS
Role: lead
Growth Hormone Study in Adults With Prader-Willi Syndrome
Role: collaborator
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
Role: collaborator
Weight Change in PWS Over Six Months
Role: lead
Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome
Role: collaborator
Proof of Concept Study of Vagus Nerve Stimulation
Role: collaborator
Prader-Willi Syndrome Macronutrient Study
Role: collaborator
Macronutrient Regulation of Ghrelin and Peptide YY
Role: collaborator
Hypoglycemia in Prader-Willi Syndrome
Role: collaborator
All 14 trials loaded